FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4315567445> ?p ?o ?g. }

• W4315567445 endingPage "191" @default.
• W4315567445 startingPage "181" @default.
• W4315567445 abstract "Background/Aims: In pediatric oncology, a Phase II trial often utilizes a safety run-in phase followed by an efficacy phase that enrolls at the dose level selected based on the safety run-in. Different from a Phase I trial, a Phase II safety run-in often assesses a very small number of dose levels. In the context of a safety run-in that assesses two or three dose levels, this article aims to compare three design methods, including the algorithm-based designs 3 + 3 and Rolling 6, and the model-assisted designs such as the Bayesian optimal interval design. Methods: Extensive simulations were conducted to evaluate and compare operating characteristics of the three design methods for a safety run-in with two or three dose levels, varying the starting dose level. Results: The performance of algorithm-based and model-assisted designs can be influenced by selection of the starting dose level, with trials starting at a lower dose level having a higher probability of selecting a low dose or considering all doses as toxic. The impact is larger for 3 + 3 and Rolling 6 but to a lesser extent for Bayesian optimal interval design. For a safety run-in with two dose levels, using 3 + 3 or Rolling 6 and starting at the higher dose often lead to similar performance to Bayesian optimal interval design. For safety run-in with three dose levels, starting at the middle dose with 3 + 3, Rolling 6 or Bayesian optimal interval design is a good compromise between improving correct dose selection and imposing a toxic dose to less patients. Conclusions: Despite being sensitive to the starting dose level, the 3 + 3, Rolling 6 and Bayesian optimal interval designs overall demonstrate reasonable performance, which can be further improved with wise selection of the starting dose level. The Rolling 6 design remains the recommended design method especially if pharmacokinetics is important or required with this design having the feature of treating six patients per dose level. When designing a safety run-in, selection of a design method or selection of a starting dose should consider both the performance of the design approaches with different choices of a starting dose level and the magnitude of safety concerns with the dose levels under investigation." @default.
• W4315567445 created "2023-01-11" @default.
• W4315567445 creator A5013274725 @default.
• W4315567445 creator A5066861312 @default.
• W4315567445 date "2023-01-11" @default.
• W4315567445 modified "2023-09-24" @default.
• W4315567445 title "Comparison of design methods for a safety run-in phase of a phase II clinical trial" @default.
• W4315567445 cites W157435900 @default.
• W4315567445 cites W1727163805 @default.
• W4315567445 cites W1976397576 @default.
• W4315567445 cites W1981851967 @default.
• W4315567445 cites W1988289042 @default.
• W4315567445 cites W2005920914 @default.
• W4315567445 cites W2006990152 @default.
• W4315567445 cites W2007276247 @default.
• W4315567445 cites W2012307210 @default.
• W4315567445 cites W2022490316 @default.
• W4315567445 cites W2044316798 @default.
• W4315567445 cites W2054383376 @default.
• W4315567445 cites W2073567145 @default.
• W4315567445 cites W2076108528 @default.
• W4315567445 cites W2078274740 @default.
• W4315567445 cites W2098980231 @default.
• W4315567445 cites W2103105040 @default.
• W4315567445 cites W2104438003 @default.
• W4315567445 cites W2110340629 @default.
• W4315567445 cites W2113073012 @default.
• W4315567445 cites W2115499099 @default.
• W4315567445 cites W2125300671 @default.
• W4315567445 cites W2140081776 @default.
• W4315567445 cites W2158740848 @default.
• W4315567445 cites W2167162853 @default.
• W4315567445 cites W2496671631 @default.
• W4315567445 cites W2525962908 @default.
• W4315567445 cites W2802492614 @default.
• W4315567445 cites W2808229831 @default.
• W4315567445 cites W2885918279 @default.
• W4315567445 cites W2922634714 @default.
• W4315567445 cites W2981808199 @default.
• W4315567445 cites W3046338417 @default.
• W4315567445 cites W3103950165 @default.
• W4315567445 cites W3174918603 @default.
• W4315567445 doi "https://doi.org/10.1177/17407745221140913" @default.
• W4315567445 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36628921" @default.
• W4315567445 hasPublicationYear "2023" @default.
• W4315567445 type Work @default.
• W4315567445 citedByCount "0" @default.
• W4315567445 crossrefType "journal-article" @default.
• W4315567445 hasAuthorship W4315567445A5013274725 @default.
• W4315567445 hasAuthorship W4315567445A5066861312 @default.
• W4315567445 hasConcept C105795698 @default.
• W4315567445 hasConcept C107673813 @default.
• W4315567445 hasConcept C114614502 @default.
• W4315567445 hasConcept C126322002 @default.
• W4315567445 hasConcept C127413603 @default.
• W4315567445 hasConcept C148482608 @default.
• W4315567445 hasConcept C151730666 @default.
• W4315567445 hasConcept C186394612 @default.
• W4315567445 hasConcept C200601418 @default.
• W4315567445 hasConcept C2777334693 @default.
• W4315567445 hasConcept C2778067643 @default.
• W4315567445 hasConcept C2779343474 @default.
• W4315567445 hasConcept C33923547 @default.
• W4315567445 hasConcept C41008148 @default.
• W4315567445 hasConcept C44249647 @default.
• W4315567445 hasConcept C535046627 @default.
• W4315567445 hasConcept C71924100 @default.
• W4315567445 hasConcept C86803240 @default.
• W4315567445 hasConceptScore W4315567445C105795698 @default.
• W4315567445 hasConceptScore W4315567445C107673813 @default.
• W4315567445 hasConceptScore W4315567445C114614502 @default.
• W4315567445 hasConceptScore W4315567445C126322002 @default.
• W4315567445 hasConceptScore W4315567445C127413603 @default.
• W4315567445 hasConceptScore W4315567445C148482608 @default.
• W4315567445 hasConceptScore W4315567445C151730666 @default.
• W4315567445 hasConceptScore W4315567445C186394612 @default.
• W4315567445 hasConceptScore W4315567445C200601418 @default.
• W4315567445 hasConceptScore W4315567445C2777334693 @default.
• W4315567445 hasConceptScore W4315567445C2778067643 @default.
• W4315567445 hasConceptScore W4315567445C2779343474 @default.
• W4315567445 hasConceptScore W4315567445C33923547 @default.
• W4315567445 hasConceptScore W4315567445C41008148 @default.
• W4315567445 hasConceptScore W4315567445C44249647 @default.
• W4315567445 hasConceptScore W4315567445C535046627 @default.
• W4315567445 hasConceptScore W4315567445C71924100 @default.
• W4315567445 hasConceptScore W4315567445C86803240 @default.
• W4315567445 hasIssue "2" @default.
• W4315567445 hasLocation W43155674451 @default.
• W4315567445 hasLocation W43155674452 @default.
• W4315567445 hasOpenAccess W4315567445 @default.
• W4315567445 hasPrimaryLocation W43155674451 @default.
• W4315567445 hasRelatedWork W2033237464 @default.
• W4315567445 hasRelatedWork W2048584407 @default.
• W4315567445 hasRelatedWork W2052137244 @default.
• W4315567445 hasRelatedWork W2198824613 @default.
• W4315567445 hasRelatedWork W2802492614 @default.
• W4315567445 hasRelatedWork W3042703790 @default.
• W4315567445 hasRelatedWork W4210616617 @default.

• next